Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Itonis Inc. (ITNS)

ITNS RSS Feed
Add ITNS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sunspotter, stealofadeal, Pennystock9449, Fishercat, YouOnlyLiveOnce, Mechanic71
Search This Board:
Last Post: 10/21/2014 9:18:40 AM - Followers: 386 - Board type: Free - Posts Today: 9

                      

Itonis Holdings



 

OTC Pink Current Information

 

Market Value
$2,470,928  a/o Mar 05, 2014


Shares Outstanding
930,377'519  a/o Aug 31, 2013

Float
551,162,197 a/o May 31, 2013
 

Authorized Shares
1,000,000,000  a/o Aug 31, 2013

http://itonisholdings.com/

and

http://paramountdiscoveries.com/

 

 

 

 

   
1. devision


ABOUT ITONIS PHARMACEUTICALS

Itonis pharmaceuticals was created as a new division of Itonis, Inc. in collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam® Cold Remedy. This innovative pharmaceutical organization will produce and market prescription homeopathic preparations and over-the-counter products to treat chronic diseases and common ailments. The company will select products based on the speed to market seeking to bypass where appropriate the traditional and lengthy FDA approval process, while still maintaining the strictest levels of both safety and efficacy.

Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.



PIPELINE

 

In late August of 2012, Itonis pharmaceuticals introduced an over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current OTC and prescription treatments.

While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it is suggested to be over half a billion dollars annually.
Itonis Pharmaceuticals plans to announce the details of upcoming human clinical studies for the nausea preparation formulation over the coming weeks as it files its provisional patents to protect its intellectual property.
 

http://itonisholdings.com/wp-content/uploads/2013/05/Emesyl2-4.jpg


MANAGEMENT TEAM

  • Charles Hensley, Ph.D

Charles Hensley, Ph.D., the inventor of Zicam® cold remedy is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic cocktails. In 1997, Dr. Hensley founded Geltech, LLC., the company that launched Zicam® and made the product a household name. With the launch of of Zicam® cold remedy, Dr. Hensley and co-workers changed the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley also developed Zicam® Allergy and the nasal delivery systems used in the Zicam® product line extensions. Dr. Hensley and his partners sold their stake in Geltech to Matrixx initiatives (MTXX).

In 2000, Dr. Hensley was president of Zengen, Inc., a bio-pharmaceutical company, and 2003 founded and served as Chairman and CEO of PRB Pharmaceuticals. He recently co-founded Universal Bio Innovations.

He received his B.S. from the University of Oklahoma and his Ph.D. in Physiology and Biophysics from the University of Southern California. He completed his post-doctoral fellowship in Molecular Cardiology at The University of Southern California in 1993. Subsequently he taught at The University of Southern California School of Pharmacy and medical students at the University of California, Riverside.

  • Mark Cheung

Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.

Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20+ staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.

Through his decade-long experience of serving and giving back to his community, Mr. Cheung found that such charitable organizations provided him first-hand experience with all aspects of the corporate and business world, including personnel, operations, financial, competition concerns, and reserve investing.

Since 2005, Mr. Cheung has also served as an adjunct professor, teaching upper-class levels at Chapman University School of Law.

Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law.
 


2. devision

VERTEX

Paramount Discoveries





 
 


How Paramount Discoveries Became A Scientific Research Company


Paramount Discoveries, Inc. is a scientific research company originally founded in 1995 by Stuart Robbins. The company is the culmination of more than 16 years of dedicated research to develop a process that can stimulate magnetism in several common natural elements and minerals.
Paramount Discoveries' technologies use an arbitrary wave form generator combined with permanent magnets, and apply a rare frequency for each element or mineral to sustain its "magnetic moment", thus controlling the element or mineral.
The 16 years of research has helped Paramount Discoveries to successfully generate these unique frequencies and overcome the overwhelming scientific odds of finding the correct frequency. Now, Paramount Discoveries continues to challenge the scientific community, researching and developing new technologies that prove the astronomical odds of discovering these frequencies are still possible.

Technology / Working on:



 

 

 

Itonis Pharmaceuticals Received Emesyl Samples for Evaluation

Feb 28, 2014

OTC Disclosure & News Service

-

Itonis Pharmaceuticals Received Emesyl Samples for Evaluation

LAGUNA HILLS, CA--(Marketwired - Feb 28, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that it has received and is currently evaluating samples of its Emesyl™ product from its manufacturer. Oasis Health Products, Inc. delivered two versions of the Emesyl™ anti-nausea formula which are currently being evaluating for tolerance.

"The two versions differ in terms of preservative," says Ernesto Barron, Itonis' recently appointed Chief Scientific Officer. "We are looking at using a class of preservative that will not only maintain product stability but also will serve to sooth the nasal passages."

About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.

Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact:
Itonis, Inc.
 
 

Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy and Itonis Pharmaceuticals to Use Its Exclusive Manufacturer for Emesyl(TM) Anti-Nausea Swab and Oral Spray Products

Posted on
 
May 3, 2013

LAGUNA HILLS, Calif., May 3, 2013 — Itonis, Inc. (ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the Company’s exclusive manufacturer (Oasis Health Products, Inc.) will produce the Company’s anti-nausea swab and its oral spray products under the Emesyl(TM) brand.

The Company expects to commence the production process with Oasis Health Products for Emesyl(TM) in both the swab and oral spray forms.

Dr. Hensley said, “We are excited that we are working with Oasis to produce the first of our Emesyl(TM) anti-nausea products. We look forward to making Emesyl(TM) available to the general public to treat nausea ailments.”

About Itonis Pharmaceuticals

Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division’s mission is to create and market over-the-counter and prescription homeopathic products that better people’s lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

 

UPDATED IBOX 9/14/2014 BELOW BY FISHERCAT

 

 ITONIS HOLDINGS 


  

    22951 Mill Creek Drive, Suite A-1
     Laguna Hills, California 92653

       Phone: (949)-200-8887
            Email: Office@ItonisHoldings.com  

         WEBSITE: http://itonisholdings.com

      EMESYL.COM   &   EMESYL.NET

       

It's been a long road, our hard work is paying off, and we are confident that Emesyl will be a household name. Sincerely, Itonis, Inc.
               $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


Press Release:   9/12/2014  EMESYL INAUGURAL PRODUCTION RUN DELIVERED FROM OASIS Posted 08:31:00 09/12/2014 by Admin
Emesyl Inaugural Production Run Delivered From Oasis Picture of the very first box of Emesyl we opened after accepting initial delivery. This is just the beginning........Hooray!

Emesyl Inaugural Production Run Delivered From Oasis on 09/12/14 Posted 08:30:00 09/12/2014 by Admin
This is the very first box of Emesyl we opened after accepting our initial delivery from Oasis Health Products! We are super excited! Stay tuned for more great news to come!

Timeline News:   CLICK HERE FOR ALL NEWS



EXCERPT FROM DR HENSLEY 6/2/2014  The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues. The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company.                                                              

 

ITONIS PHARMACEUTICALS

Itonis pharmaceuticals was created as a new division of Itonis, Inc. in collaboration with world-famous Dr. Charles Hensley, the inventor of the Zicam(R) Cold Remedy. This innovative pharmaceutical organization will produce and market prescription homeopathic preparations and over-the-counter products to treat chronic diseases and common ailments. The company will select products based on the speed to market seeking to bypass where appropriate the traditional and lengthy FDA approval process, while still maintaining the strictest levels of both safety and efficacy.

Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of Geltech, LLC, the company that launched the Zicam(R) Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

Dr. Hensley commented, "We had wide success upon creating the Zicam? Cold Remedy and I believe that similar preparations can be created to treat many other common ailments. We plan to launch several products into this derivative pharmaceutical category over the coming months. It is exciting to be a part of this new venture and we plan to move expeditiously into the marketing of the formulations that we plan to announce."

Dr. Hensley has joined Itonis as President of its Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions.
 
 
:
Charles Hensley, Ph.D., Inventor of Zicam(R) Cold Remedy, and Itonis Pharmaceuticals Announce First Product IRVINE, CA--(Marketwire - Aug 20, 2012) - Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) cold remedy, are pleased to announce plans to introduce their first product offering since the creation of Itonis Pharmaceuticals, a division of Itonis. The new division will concentrate on marketing over-the-counter and prescription preparations to treat both common ailments and chronic diseases.

Over the coming weeks, Dr. Hensley and Itonis Pharmaceuticals will outline plans to introduce into the marketplace an over-the-counter, systemically active preparation delivered via a nasal and/or sublingual spray for the alleviation of mild to moderate nausea caused by motion sickness, dizziness, migraine, gastroenteritis, food poisoning, and possibly by chemotherapy, without many of the common side effects associated with current OTC and prescription treatments.

Dr. Hensley commented, "I consult for many corporations in the product development and strategic marketing arena but I am especially excited about leading the Itonis Pharmaceuticals team in bringing this product to market. I believe the time is right to begin introduction of what I believe will be a revolutionary product. There have been relatively few innovations within this product category over the past few years and we believe the market is ripe for a new type of nausea preparation that is available over-the-counter. We believe this new preparation will be both safe and effective for a wide range of nausea related conditions."

While the actual size of the market for nausea related drugs and preparations is difficult to estimate, it is suggested to be over half a billion dollars annually.

Itonis Pharmaceuticals plans to announce the details of upcoming human clinical studies for the nausea preparation formulation over the coming weeks as it files its provisional patents to protect its intellectual property.

Dr. Hensley has joined the Itonis team to lead the Itonis Pharmaceuticals division that Itonis expects to convert into a new subsidiary. The mission of Itonis Pharmaceuticals is to create science-based products to alleviate symptoms of common ailments and chronic conditions. These preparations will be categorized as derivative pharmaceuticals in that while the preparations will be both safe and effective, the path to market is faster than traditional pharmaceutical drugs.
 

Emesyl packaging with UPC Code
CLICK HERE FOR PACKAGE DETAIL
 

Itonis Pharmaceuticals Announces First Emesyl® Manufacturer Production Release Date 
LAGUNA HILLS, CA--(Marketwired - Aug 12, 2014) - Itonis, Inc. (PINKSHEETS: ITNS)
Itonis is very excited to announce that the procurement of raw materials for its first production run of Emesyl® is over 90% complete according to its manufacturer, Oasis Health Products.
The actual manufacturing of the company's Emesyl® product is on schedule to begin August 18, 2014. We are pleased to be able to make these dates available to our shareholders. The completion and release of final product, including Quality Control testing will be September 12, 2014.
"We have been working very closely with Oasis and are pleased that the required lead times to procure packaging and raw product materials have been accurate, ensuring confidence that our timelines are met. We're fully confident of the final product release date of September 12, and heavy focus is now in place on getting solid distribution orders. It won't be long before Emesyl® will be available for retail purchase," said Dr. Charles B. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.

We are looking forward to these dates being met and distribution to begin for our flagship product Emesyl®, and will be updating shareholders with more information soon.

Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run
LAGUNA HILLS, CA--(Marketwired - Jun 25, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl® homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run. The Company is excited that we have finally developed Emesyl® to start production. We are in good hands with Oasis Health Products and we cannot wait for the first Emesyl® that we can proudly market and place on store shelves," says Mark Cheung, the Company's CEO.

Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product

LAGUNA HILLS, CA--(Marketwired - Jun 2, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl® over-the-counter homeopathic product for nausea relief. In addition, the Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office for its Emesyl® trademark. The NDC number and trademark Notice of Allowance has enabled the Company to enter the final stage of its product packaging design, and the production of Emesyl® will soon begin with its manufacturer, Oasis Health Products. The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues.
"Reaching these significant NDC and trademark milestones required a lot of hard work and patience. We have wasted no time in prompting our manufacturer to finalize all steps for the first production run of Emesyl®, bringing us one step closer to market," said Dr. Charles B. Hensley, the inventor of Emesyl® and the Zicam® Cold Remedy.
The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription
30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company. (http://pharma.about.com/od/Over-the-Counter-Medicine/a/The-Over-the-counter-Drug-Industry.htm)

Itonis Pharmaceuticals Received Emesyl Samples for EvaluationLAGUNA HILLS, CA--(Marketwired - Feb 28, 2014) 
Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that it has received and is currently evaluating samples of its Emesyl™ product from its manufacturer. Oasis Health Products, Inc. delivered two versions of the Emesyl™ anti-nausea formula which are currently being evaluating for tolerance.

"The two versions differ in terms of preservative," says Ernesto Barron, Itonis' recently appointed Chief Scientific Officer. "We are looking at using a class of preservative that will not only maintain product stability but also will serve to sooth the nasal passages."

*****************************************************************************************************************************************************************************

MANAGEMENT TEAM
Dr.Charles B. Hensley, PH.D
President of Itonis Holdings


Dr. Charles B. Hensley is the pioneer in the development and use of safe and effective therapeutic cocktails. He is a graduate of the University of Oklahoma and received his Ph.D. in Physiology and Biophysics from the University of Southern California.
In the mid 1990's, Dr. Hensley invented of Zicam(R) cold remedy, one of the top cold remedies in the United States. With the launch of ZICAM, Dr. Hensley and co-workers changed the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley also developed Zicam(R) Allergy and the nasal delivery systems used in the Zicam(R) product line extensions.
Dr. Hensley was CEO and Chairman of Nasal Therapeutics, Inc., CEO of PRB Pharmaceuticals, president of Zengen, and co-founder of Zicam, LLC (formerly Geltech, LLC).

Mark Cheung CEO / President


Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.
Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20 staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.
Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law.

Steve Pidliskey Vice President / Secretary


Mr. Pidliskey serves as Vice President and Secretary for Itonis, Inc. He is responsible for the management of all company operations and is a visionary leader with a proven track record in motivating, managing and growing large multi-level teams in support of new products and services.
Prior to joining Itonis, Inc. in 2011, Mr. Pidliskey was a Project Executive for IBM Corporation, retiring after a 32 year career. During his tenure with IBM, he was responsible for worldwide sales and services support with contract revenues exceeding $1B annually. He has extensive experience in leading large complex teams responsible for business operations, strategic planning, change management, business process reengineering, and technical sales support. As an Innovative leader, Mr. Pidliskey is known for building strong teams, integrating strategic business partnerships, and delivering high levels of client satisfaction to customer sets ranging from small and medium size businesses to Fortune 500 companies.
Within his community, Mr. Pidliskey has served as a county board member for more than 20 years to a local county government Citizens Advisory Council. He has held several executive positions on the council, and meets monthly with government and community leaders to assist in the development and perpetuation of crime prevention programs in support of law enforcement services. In addition, Mr. Pidliskey has served for over 10 years as a committee member to a local Boy Scout troop and remains active in leading fund raising activities in support of the Boy Scouts of America.

Donald Jolly, Ph.D.  CFO / Treasurer


Dr. Donald L. Jolly, Ph.D. has more than 20 years experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a California bank provided him valuable experience in managing the early developments of a business.
Dr. Jolly also serves as the Chairman and CEO of the Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in Hyperbarics. He has studied in London, Aberdeen, Scotland and California with internationally renowned doctors, developed research facilities in California, worked in Africa and Romania, and made great strides in research as well as the application of Hyperbaric Oxygen Therapy (HBOT). This pursuit has supplemented his banking career with additional operational and business growth experience. 

Oasis | Contract Manufacturing, Private Label Manufacturer, Homeopathy
Oasis Health Products to Provide Manufacturing Services for Itonis Pharmaceuticals Anti-Nausea ProductsLAGUNA HILLS, Calif., May 2, 2013
Itonis, Inc. (ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam(R) Cold Remedy, and founding member of Itonis Pharmaceuticals, are pleased to announce that the Company has entered into a manufacturing agreement with Oasis Health Products, Inc. to manufacture Emesyl(TM), the company's over-the-counter homeopathic products for the relief of nausea.
Dr. Hensley commented, Oasis Health Products was our first choice as our manufacturer for our homeopathic products and we are extremely pleased that they will be providing us with comprehensive contract manufacturing services for our anti-nausea products. Please visit http://www.oasishp.com for additional information.


 

Security Symbol: ITNS   
OTC PINK
Share Structure

Market Value: $6,977,831 a/o Aug 8, 2014
Shares Outstanding: 930,377,519 a/o May 31, 2014
Preferred Shares: 5,000,000
Float: 551,162,197 a/o May 31, 2014
Authorized Shares: 1,000,000,000 a/o May 31, 2013
Par Value: 0.001
Shareholders of Record: 662 a/o May 31, 2014
Number of Beneficial Shareholders: Approx 1
Total number of Shareholders: 662

 

 
 

.



 


 

 


 

 

News News Alert: Itonis Pharmaceuticals Announces Emesyl® Website on New Nausea Relief Product 10/21/2014 09:00:00 AM
PostSubject
#26495  Sticky Note Just a reminder, ITNS is not a PR lordofinvest 09/12/14 06:52:50 PM
#22188  Sticky Note "I'm a bit surprised that you haven't linked sunspotter 06/06/14 03:40:48 AM
#27559   I am no expert at doing a query hebroots 10/21/14 09:18:40 AM
#27558   Now there are MORE delays, as they process hebroots 10/21/14 09:15:41 AM
#27557   Believe the worst? Only for a quick Moroski 10/21/14 09:00:45 AM
#27556   From Emesyl.com kpisme 10/21/14 08:34:28 AM
#27555   Why? It's all a scam....remember? Just ask "they profiteer11 10/21/14 08:17:13 AM
#27554   What news are you speaking of? vodkadejour 10/21/14 07:43:27 AM
#27553   Allright. Now things are heating up. Fins and Dr Badman 10/21/14 06:22:16 AM
#27552   Emesyl.com has been upgraded also. rugies 10/21/14 05:52:39 AM
#27551   New packaging design @ Itonisholdings.com! Smoov7333 10/21/14 04:34:21 AM
#27550   Agree100% 569 is a very low float for YouOnlyLiveOnce 10/20/14 09:03:13 PM
#27549   Nice. Far from the estimate someone gave here Moroski 10/20/14 08:49:25 PM
#27548   Q3 OUT FLOAT 570 MILL YouOnlyLiveOnce 10/20/14 08:36:34 PM
#27547   Why isn't IHUB showing the news for ITNS? JGPierce 10/20/14 08:30:56 PM
#27546   How many is a FEW in tweeter talk? kpisme 10/20/14 02:53:53 PM
#27545   One conspiracy theory would be that its all profiteer11 10/20/14 02:34:38 PM
#27544   How does that trade happen at .0071 earlier Moroski 10/20/14 01:40:35 PM
#27543   All I can see right now is 3m Speedbucket 10/20/14 10:56:22 AM
#27542   I don't have lev 2 - what does Moroski 10/20/14 10:25:59 AM
#27541   There are those 1 share trades again. Moroski 10/20/14 10:25:12 AM
#27540   I think if we can get some volume, Speedbucket 10/20/14 10:20:21 AM
#27539   We all know it. Just churning what seems Moroski 10/20/14 10:10:16 AM
#27538   ITNS will be huge! vodkadejour 10/20/14 01:00:51 AM
#27537   sweet little tweet; I taught I saw a hebroots 10/18/14 07:07:28 PM
#27536   Agreed. That sweet little tweet said buy buy. Dr Badman 10/18/14 02:37:45 PM
#27535   ITNS, great things coming sampa 10/18/14 02:32:20 PM
#27534   Your right...Rewards way out way the risks..!!.. Just Gman24 10/18/14 11:01:23 AM
#27533   I like the statement mentioned on another board Moroski 10/18/14 10:52:48 AM
#27532   Agree... My finger will be on the trigger..!!! Gman24 10/18/14 10:42:38 AM
#27530   Lol, and only one of these are not kknd1021 10/17/14 09:38:36 PM
#27529   Good lord - the media is crazy. Selling Moroski 10/17/14 06:16:10 PM
#27528   cool, I figure it is either follow this hebroots 10/17/14 05:37:11 PM
#27527   And no crazy 100 or 1 share exchange Moroski 10/17/14 04:52:50 PM
#27526   Thanks hebroots. You know I gave you a Moroski 10/17/14 04:51:56 PM
#27525   They have 5 business days from Oct 14, hebroots 10/17/14 04:04:00 PM
#27524   I saw that they have 5 days more Moroski 10/17/14 03:57:32 PM
#27523   we will have to see the latest report hebroots 10/17/14 03:50:32 PM
#27522   right, there would have to be some options hebroots 10/17/14 03:49:29 PM
#27521   Their extremely poor excuse for the last quarterly hebroots 10/17/14 03:48:01 PM
#27520   I see no dilution. There is no millionlafs 10/17/14 03:42:49 PM
#27519   We can only be sure of anything under YouOnlyLiveOnce 10/17/14 03:11:46 PM
#27518   Etrade shows OS=852.0M... Float=843.5M millionlafs 10/17/14 03:08:51 PM
#27517   Precisely my point. :-) millionlafs 10/17/14 02:54:36 PM
#27516   And if you think about it--the last PR Moroski 10/17/14 02:54:18 PM
#27515   So the float is an educated guess? Moroski 10/17/14 02:47:06 PM
#27514   200 into 1000 that's not "ridiculous".. Its magical YouOnlyLiveOnce 10/17/14 02:45:05 PM
#27513   It is a small risk to bet $200 millionlafs 10/17/14 02:43:07 PM
#27512   "Ridiculous" IMO traders spend what they can when YouOnlyLiveOnce 10/17/14 02:35:18 PM
#27511   IMO the conversions where finalized on the last Q YouOnlyLiveOnce 10/17/14 02:32:07 PM
#27510   The float is basically the total shares outstanding hebroots 10/17/14 02:22:58 PM
#27509   No, it hasn't. millionlafs 10/17/14 02:18:13 PM
PostSubject